News & Events

Candid Advice For Cash-Strapped Startups From A Biotech Venture Capitalist

By Josh Baxt, BioSpace.com Exclusive Story July 21, 2014 In a sense, Niall O’Donnell, Ph.D., and his colleagues at RiverVest Venture Partners run a biomedical adoption agency. They track down innovative discoveries, help raise them for a while and then find a good home, either at a pharmaceutical company or through public markets. For cash-strapped startups, this represents an opportunity, but they need to understand the rules. RiverVest is trying to build companies in five years or less, and that means having excellent IP and a...

read more

ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with Hyperkalemia

Company expects to announce top-line results late Q3 or early Q4 2014 Coppell, Texas – July 14, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has completed enrollment in ZS004, its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate), a novel investigational treatment for hyperkalemia. This randomized, double-blind, placebo-controlled study is designed to confirm, over a longer treatment period, the positive...

read more

Otonomy Files Registration Statement for Proposed Initial Public Offering

SAN DIEGO, July 14, 2014 /PRNewswire/ – Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy. The number of...

read more

ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9

Applications cover composition of matter and methods of treating hyperkalemia and carry a patent term to at least 2032 Coppell, Texas – July 8, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Numbers 13/371,080 and 14/036,489 for ZS-9 (sodium zirconium cyclosilicate), the Company’s product candidate in Phase 3...

read more

ZS Pharma Announces Start of Enrollment of Phase 3 Long-Term Maintenance Study of ZS-9 in Patients with Hyperkalemia

–Open-Label Safety Study Evaluating Long-Term Safety and Efficacy of Oral Investigational Hyperkalemia Treatment— Coppell, Texas – June 26, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has begun enrolling patients in ZS005, a Phase 3 open-label, 12-month, long-term maintenance study of ZS-9, an investigational treatment for hyperkalemia. This Phase 3 trial is designed to further add to the clinical experience to date by...

read more

ZS Pharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Coppell, Texas – June 23, 2014 – ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 891,667 additional shares of common stock. The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other...

read more

ZS Pharma, Inc. Announces Pricing of Initial Public Offering

COPPELL, Texas–(BUSINESS WIRE)– ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the pricing of its initial public offering of 5,944,444 shares of its common stock at a price to the public of $18.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on June 18, 2014 under the symbol “ZSPH”. In addition, ZS Pharma has granted the underwriters a 30-day option to purchase up to an additional 891,667...

read more

ZS Pharma to Present Data from Phase 3 Trial of ZS-9 in Late-Breaking Poster Presentation at the American Diabetes Association (ADA) Scientific Sessions

Coppell, Texas – June 13, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from a pivotal Phase 3 trial of ZS-9, its investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trial poster during the 74th American Diabetes Association (ADA) Scientific Sessions being held in San Francisco from June 13 to 17, 2014. The Company’s Phase 3 trial, ZS003, assessed the safety and efficacy of ZS-9 in...

read more

ZS Pharma to Present Data from Phase 3 Trial of ZS-9 in Late-Breaking Poster Presentation at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

Coppell, Texas – May 28, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from a pivotal Phase 3 trial of ZS-9, its investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trials poster presentation during the 51st European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress being held in Amsterdam from May 31 to June 3, 2014. The Company’s Phase 3 trial, ZS003,...

read more

15 Agents of Change in Medtech: No. 7: RiverVest Venture Partners

Medical Device and Diagnostic Industry May 28, 2014 Jamie Hartford  No. 7: RiverVest Venture Partners Passion or the desire to make a difference alone cannot bring about radical changes in the world of medtech. Money and the right guidance are equally crucial. That’s where venture capitalist firms—especially RiverVest Venture Partners—come in.  Read More

read more